Sterilised, Porcine Placental Tissue in the Treatment of Chronic Diabetic Foot Ulcers

Not Applicable

Completed

• Conditions: Diabetic Foot Ulcer
• Interventions: Device: InnovaMatrix AC porcine placental ECM therapy

• Registration Number: NCT05687656
• Lead Sponsor: ConvaTec Inc.

Brief Summary

A Prospective, Non-Randomized, Multi-Center Observational Study

To determine the safety and effectiveness of InnovaMatrix AC porcine placental ECM therapy for the treatment of chronic, non-healing diabetic foot ulcers (DFUs)

Eligible subjects will be treated with a weekly application of sterilized, porcine placental ECM followed by standard of care wound therapy and offloading

Detailed Description

This is a prospective, multi-center observational study . The trial will include 30 completed subjects at three (3) experienced clinical centers in the United States. The estimated enrollment period is 13 weeks. After completing a screening , the subjects will be enrolled and receive treatment followed for at least 12 weeks.

It is expected that the majority of the subjects will be recruited from patients being seen in the Investigators' practices. No minors will be included in the study and it is anticipated that there will be a roughly equal representation of male and female subjects. Further, no subjects will be excluded because of race or ethnicity and all efforts will be made to adequately represent the study population in the area in which they are chosen.

All subjects will be used for the analysis of efficacy and safety data.

Study Timeline

• Study Start: 2022-10-06
• Study First Submitted: 2022-12-02
• Study First Submitted QC: 2023-01-06
• Study First Posted: 2023-01-18
• Primary Completion: 2024-01-31
• Study Completion: 2024-01-31
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-30
• Last Update Posted: 2024-05-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

1. Index Ulcer Assessment:

   1. Penetrates down to muscle, tendon, or bone
   2. Presence of another diabetic foot ulcer within 2 cm of the index ulcer
   3. Index ulcer determined to be due to Active Charcot deformity or previous surgical correction for Charcot deformity.
   4. Wounds which occur in relation to major structural abnormalities of the foot, which would include amputations related to osteomyelitis or Charcot deformity
   5. Exhibits overt clinical signs and symptoms of infection with cellulitis surrounding the wound margin.
   6. Known or suspected local skin malignancy to the index diabetic ulcer
   7. Wound duration > one year without intermittent closure

2. Prior therapies - Subjects receiving treatment with any of the following will not be eligible for enrollment:

   1. In the last 7 days - Negative pressure wound therapy (wound vac or SNaP®) of the index ulcer
   2. In the last 7 days - Hyperbaric oxygen (HBO) therapy
   3. In the last 10 days - Chemical debridement, hypochlorous acid or Dakin's solution, medical honey therapy
   4. In the last 30 days - Treatment with cytotoxic chemotherapy, application of topical steroids to the ulcer surface, or use of ≥ 14 days of immune-suppressants (including systemic corticosteroids); or, subject is anticipated to require such medications during the course of the study
   5. In the last 30 days - study ulcer treatment with any advanced therapy, including, biomedical or topical growth factors, tissue engineered materials (e.g. Apligraf or Dermagraft), sterilized placental allografts (EpiFix, NovaFix, etc.), or other scaffold materials (e.g. OASIS® Wound Matrix, MatriStem Wound Matrix )
   6. In the last 30 days - Subject has been on any investigational drug(s) or therapeutic device(s)
   7. In the last 8 weeks - Amputation or revascularization (surgical or stenting) to the affected leg

3. Subject criteria that will make subject ineligible for enrollment:

   1. Known hypersensitivity to porcine based products
   2. Known osteomyelitis or active cellulitis requiring antimicrobial therapy at wound site
   3. End stage renal disease requiring dialysis.
   4. Immune system disorders including Systemic Lupus Erythematosus (SLE), Acquired Immunodeficiency Syndrome (AIDS) or HIV
   5. Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of or compliance with the study protocol in the judgment of the Investigator
   6. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women of childbearing potential who are planning to become pregnant during the time of the study OR are unwilling/unable to use acceptable methods of contraception (birth control pills, barriers, or abstinence)
   7. Subjects currently enrolled in this study. Concurrent enrollment in the study is prohibited
   8. Subjects currently receiving radiation therapy or chemotherapy
   9. Any pathology that would limit the blood supply and compromise healing or non-revascularizable surgical sites

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
InnovaMatrix AC porcine placental ECM therapy	InnovaMatrix AC porcine placental ECM therapy	Eligible subjects will be treated with a weekly application of sterilized, porcine placental ECM followed by standard of care wound therapy and offloading

Primary Outcome Measures

Name	Time	Method
Wound Healing area using digital image	12 weeks	The primary endpoint for the study is assessment of ulcer area at Weeks 6 and 12 using the MolecuLight Imaging Device

Secondary Outcome Measures

Name	Time	Method
Wound Closure	12 weeks	Time to complete wound closure as defined by FDA
Percentage area reduction	12 weeks	• Rate of wound closure as assessed by wound area measurements determined by weekly percent area reduction
Adverse events	12 weeks	Adverse events as reported at weekly treatment visits

Trial Locations

Locations (5)

Three Rivers Hyperbaric and Wound Center; 🇺🇸 North Port, Florida, United States

Serena Group Buffalo Research Center; 🇺🇸 Buffalo, New York, United States

SerenaGroup Monroeville; 🇺🇸 Monroeville, Pennsylvania, United States

SerenaGroup Austin Research Center; 🇺🇸 Austin, Texas, United States

Atrium Medical Center; 🇺🇸 Stafford, Texas, United States